When Hormones Affect the Mind Perimenopause, Menopause, and Mental Health

An evidence-based guide for recognizing the often-overlooked connection between hormonal change, sleep, mood, anxiety, and depression.

A woman in her 40s may begin experiencing anxiety that seems to come from nowhere. She may feel unusually irritable, emotionally overwhelmed, or unlike herself. She may fall asleep easily but wake at 2:00 or 3:00 in the morning with a racing mind - and be unable to return to sleep.

Because her menstrual cycles are still regular and she is not having hot flashes, neither she nor her clinician may consider perimenopause.

Yet changes in sleep, mood, anxiety, concentration, and emotional resilience can be among the earliest symptoms of the menopause transition. They may begin before obvious menstrual changes or hot flashes appear.

For many women, the first sign of perimenopause is not a missed period. It is the feeling that something has changed in their brain.

Perimenopause Is a Neurological Transition

Menopause is often described as the end of a woman's reproductive years, but it is not simply a reproductive event. It is also a neurological and physiological transition.

Estradiol, progesterone, and testosterone do much more than regulate menstrual cycles and reproductive function. Receptors for these hormones are found throughout the brain, including areas involved in:

• Mood and emotional regulation

• Sleep

• Memory and concentration

• Motivation and reward

• Sexual response

• Temperature regulation

• The stress response

Estradiol interacts with neurotransmitter systems including serotonin, dopamine, norepinephrine, glutamate, and GABA. These chemical messengers influence mood, motivation, attention, sleep, and the way the brain responds to stress.

Progesterone and its metabolites also interact with the brain's GABA system, which has calming and sleep-supporting effects.

During perimenopause, hormone levels do not decline in a smooth, predictable line. Estradiol may rise dramatically and then fall, while ovulation becomes less consistent and progesterone production may decrease. The brain must continually adapt to these changing signals. For women who are particularly sensitive to reproductive hormone fluctuations, this instability may contribute to anxiety, irritability, depressive symptoms, disrupted sleep, and a decreased ability to manage stress.

Testosterone Matters to the Female Brain, Too

Testosterone is not exclusively a male hormone. Women produce it in the ovaries and adrenal glands, although in smaller amounts than men. Androgen receptors are found in brain regions involved in motivation, reward, sexual response, cognition, and emotional processing. Testosterone also interacts with neurotransmitter pathways, including dopamine, that contribute to interest, motivation, pleasure, and engagement with life.

When androgen activity changes, some women report reduced sexual desire or pleasure, diminished motivation, reduced energy, feeling emotionally flat, lower confidence, or difficulty concentrating. These experiences can overlap with depression, medication effects, chronic stress, sleep deprivation, thyroid disease, iron deficiency, and changing estradiol and progesterone levels. Symptoms alone cannot determine whether testosterone is the cause.

Sexual health is closely connected to mental health. Persistent loss of desire or response can affect confidence, body image, relationships, and connection. Conversely, depression, anxiety, pain, poor sleep, relationship concerns, and some psychiatric medications - particularly certain antidepressants - can reduce desire. A biological, psychological, and social assessment is therefore essential.

Why Testosterone Is Often Overlooked

Testosterone has historically been labeled a male hormone, while menopause education has focused primarily on estrogen and progesterone. Female testosterone research has also received far less attention than male testosterone research.

There is no single testosterone level that defines a female androgen-deficiency syndrome, and blood levels do not consistently correspond with symptoms. Measurement is challenging because women's concentrations are much lower than men's. A blood test can support safe prescribing and monitoring, but it cannot independently establish that testosterone is responsible for low mood, fatigue, or reduced desire.

Testosterone's trajectory is also complex. Levels change with age, ovarian function, medications, and certain medical or surgical conditions; they do not necessarily fall suddenly at the final menstrual period. In addition, there is no FDA-approved testosterone product specifically formulated for women in the United States. These limitations, together with gaps in education and research, help explain why testosterone is frequently absent from the menopause conversation.

Can Testosterone Therapy Improve Mental Health?

Research is examining whether testosterone therapy may affect mood, motivation, cognition, or energy in selected women. Some women report improvement, but current evidence is not sufficient to recommend testosterone as a treatment for depression, anxiety, cognitive concerns, or general fatigue.

International consensus guidance identifies the clearest evidence-based indication as hypoactive sexual desire disorder (HSDD) in appropriately assessed postmenopausal women. HSDD is persistent low sexual desire that causes personal distress and is not better explained by medication effects, a psychiatric condition, relationship factors, pain, or another medical problem.

When treatment improves distressing low desire, pleasure, and intimate connection, emotional well-being may improve indirectly. Testosterone should not, however, replace psychiatric evaluation or evidence-based treatment for depression or anxiety. When prescribed, it requires careful selection, physiologic female dosing, and monitoring by an experienced clinician. Supraphysiologic dosing can cause androgenic adverse effects.

Testosterone is biologically relevant to women's brains and well-being, but biologic plausibility is not the same as proven therapeutic benefit.

Mental Health Symptoms May Appear First

Many women have been taught to look for hot flashes and irregular periods as the first signs of perimenopause. Although those symptoms are common, they do not always appear first. Research on the earliest manifestations of the transition identifies mood changes and sleep problems - along with vasomotor and sexual symptoms - as features that can emerge early. A woman may still have predictable cycles while experiencing:

• New or worsening anxiety

• Irritability or a shorter temper

• Depressed mood, frequent crying, or emotional sensitivity

• Feeling overwhelmed by situations she previously managed well

• Loss of motivation or pleasure

• Difficulty concentrating, forgetfulness, or brain fog

• Trouble falling asleep, staying asleep, or early-morning awakening

• Panic symptoms or heart-racing sensations

• Worsening premenstrual mood symptoms

• A feeling of no longer being herself

These symptoms should not automatically be attributed to hormones. Thyroid disorders, anemia, medication effects, sleep apnea, substance use, major depression, anxiety disorders, bipolar disorder, trauma, and significant life stressors must also be considered.

Perimenopause should nevertheless be part of the evaluation - especially when symptoms begin or worsen between approximately ages 35 and 55, vary with the menstrual cycle, or occur alongside other possible hormonal symptoms.

The Risk of Depression Increases During Perimenopause

The menopause transition represents a period of increased vulnerability to depression. In the Harvard Study of Moods and Cycles, women without a previous history of major depression who entered perimenopause were approximately twice as likely to develop significant depressive symptoms as women who remained premenopausal.

A 2024 systematic review and meta-analysis involving more than 9,000 women likewise found a significantly higher risk of depressive symptoms and depression diagnoses during perimenopause than before the transition.

Women may be especially vulnerable if they have a history of:

• Depression or anxiety

• Premenstrual dysphoric disorder (PMDD)

• Postpartum depression

• Mood sensitivity during previous hormonal transitions

• Significant sleep disruption

• Severe hot flashes or night sweats

• Recent trauma, caregiving demands, relationship stress, or other major life events

Hormones are not the only influence on midlife mental health. Many women are simultaneously managing careers, children, aging parents, relationship changes, health concerns, and chronic stress. Perimenopause can reduce the emotional and physical reserve they previously relied upon. This does not mean symptoms are 'just hormones.' It means biology, sleep, psychological health, and life circumstances must be evaluated together.

Sleep Is Both a Symptom and an Amplifier

Sleep disruption is one of the most common and consequential symptoms of the menopause transition. A woman does not have to recognize night sweats to experience hormonally related sleep disruption. Changes in temperature regulation and sleep systems may contribute to lighter sleep, frequent awakening, or early-morning awakening. Anxiety and racing thoughts may make returning to sleep difficult.

Poor sleep can intensify anxiety, irritability, depressive symptoms, emotional reactivity, difficulty concentrating, fatigue, food cravings, and loss of motivation. This creates a self-reinforcing cycle: hormonal instability disrupts sleep, and chronic sleep loss makes mood and cognitive symptoms more difficult to manage.

Assessment should also consider primary insomnia, restless legs syndrome, medication effects, alcohol use, and obstructive sleep apnea. After menopause, sleep apnea may present as insomnia, fatigue, headache, anxiety, or depression rather than obvious snoring.

Can Hormone Therapy Help?

For an appropriately selected woman, individualized hormone therapy may help restore greater hormonal stability and improve symptoms that are disrupting quality of life. This most commonly involves estradiol and, for a woman with a uterus, appropriate endometrial protection with progesterone or a progestogen. Testosterone may be considered in carefully selected women with distressing low sexual desire after comprehensive evaluation.

Hormone therapy is the most effective treatment for menopausal hot flashes and night sweats. When these symptoms cause repeated awakening, treating them can improve sleep - and better sleep often supports mood, cognition, and emotional regulation.

Clinical trials have also found that transdermal estradiol can reduce depressive symptoms in some perimenopausal women. One randomized trial found that transdermal estradiol with intermittent micronized progesterone reduced the development of clinically significant depressive symptoms compared with placebo.

Hormone therapy is not a universal treatment for every mental health condition. Estrogen is not FDA-approved specifically to treat depression, and evidence is strongest during perimenopause, particularly when sleep disruption or vasomotor symptoms coexist. For major depressive disorder, psychotherapy and antidepressant medication remain evidence-based treatments. Some women benefit from hormone therapy, some need psychiatric treatment, and others do best with a thoughtful combination of:

• Hormone therapy when clinically appropriate

• Antidepressant or anti-anxiety medication

• Psychotherapy

• Cognitive behavioral therapy for insomnia

• Treatment of sleep apnea or another sleep disorder

• Regular physical activity and resistance training

• Adequate nutrition

• Reduced or eliminated alcohol

• Stress-management support

The goal is not to decide whether symptoms are hormonal or psychiatric. The goal is to recognize that both systems can be involved and to treat the whole woman.

Hormone Testing Does Not Tell the Whole Story

A single 'normal' hormone level does not rule out perimenopause. Hormone levels can fluctuate widely from one day - or even one hour - to another. For most women over 45, perimenopause is identified primarily through age, symptoms, menstrual history, and clinical evaluation rather than one isolated estradiol or follicle-stimulating hormone measurement. For women younger than 45, or when symptoms are unusual, testing may help evaluate other conditions or possible early menopause. A woman should not be told that her symptoms cannot be related to perimenopause simply because she is still menstruating or because one laboratory result was within range.

Better Care Requires Collaboration

Psychiatric clinicians are essential for identifying and treating depression, anxiety, bipolar disorder, trauma-related conditions, and other mental health concerns. Menopause-informed clinicians can assess whether reproductive hormone changes, vasomotor symptoms, sexual concerns, or sleep disruption may also be contributing.

Collaborative care asks a more useful question:

What biological, psychological, sleep-related, and life factors are contributing to this woman's symptoms - and how can we address them together?

Women should not have to choose between mental health care and menopause care. Both may be necessary, and together they can be far more effective.

You Are Not Losing Yourself

If you are experiencing new anxiety, low mood, irritability, poor sleep, reduced desire, or difficulty

concentrating in your late 30s, 40s, or early 50s, these symptoms deserve a thorough evaluation. They should not be dismissed as aging, stress, or something you simply have to endure.

Perimenopause may not explain every mental health symptom, but it is an important and frequently overlooked part of the clinical picture. Recognizing the connection allows women to receive more complete, individualized care - and to understand that what they are experiencing is real and treatable.

You are not failing to cope. Your brain and body may be responding to a major hormonal transition, and help is available.

If you are experiencing thoughts of suicide or self-harm, seek immediate help by calling or texting 988 in the United States, calling emergency services, or going to the nearest emergency department.

References

1. Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression. Journal of

Women's Health. 2019;28(2):117-134. PubMed.

2. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new-onset depression during the menopausal transition. Archives

of General Psychiatry. 2006;63(4):385-390. Article.

3. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women

with no history of depression. Archives of General Psychiatry. 2006;63(4):375-382. Article.

4. Badawy Y, Spector A, Li Z, Desai R. The risk of depression in the menopausal stages: a systematic review and meta-analysis.

Journal of Affective Disorders. 2024. Article.

5. Gracia CR, Freeman EW. Onset of the menopause transition: the earliest signs and symptoms. Obstetrics and Gynecology Clinics

of North America. 2018;45(4):585-597. PubMed.

6. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Leserman J, Girdler SS. Efficacy of transdermal estradiol and micronized

progesterone in the prevention of depressive symptoms in the menopause transition. JAMA Psychiatry. 2018;75(2):149-157.

PubMed.

7. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal

women. Archives of General Psychiatry. 2001;58(6):529-534. PubMed.

8. Kravitz HM, Zhao X, Bromberger JT, et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample

of women. Sleep. 2008;31(7):979-990. PubMed.

9. The Menopause Society. Mental health and menopause. Patient education resource.

10. The Menopause Society. Hormone therapy. Patient education resource.

11. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women.

Journal of Clinical Endocrinology & Metabolism. 2019;104(10):4660-4666. Full text.

12. Parish SJ, Simon JA, Davis SR, et al. ISSWSH clinical practice guideline for the use of systemic testosterone for hypoactive

sexual desire disorder in women. Journal of Sexual Medicine. 2021;18(5):849-867. Full text.

13. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and

meta-analysis of randomized controlled trial data. Lancet Diabetes & Endocrinology. 2019;7(10):754-766. PubMed.

Educational disclaimer

This article is for general education and is not a substitute for individualized medical or psychiatric care. Hormone therapy and psychiatric treatment should be selected through an individualized assessment of symptoms, medical history, risks, preferences, and treatment goals.